Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab vs Regorafenib/TAS-102 in non–MSI-H/dMMR mCRC
CTR20211601Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20211601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211601.